BLU-448 / Sanofi, Blueprint Medicines - LARVOL DELTA

Characterization of BLU-448: A potent and selective degrader of CDK4 for the treatment of HR+/HER2- breast cancers (AACR 2026) - "With its remarkable potency in driving CDK4 degradation and superior selectivity over CDK6, BLU-448 holds promise as a potential best-in-class treatment for HR+/HER2- breast cancers —and possibly beyond."

Late-breaking abstract • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • CRBN • HER-2